A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

[21] Ribeiro RC(2015)Combinatorial targeting of XPO1 and FLT3-ITD exerts synergistic anti-tumor effects in FLT3-mutated acute myeloid leukemias Blood 126 Abstract 1266-1683

[22] Pui CH(2006)Prognostic significance of Ki67-negative blast cell clone in the high risk group of children treated for acute myeloid leukaemia Folia Histochem Cytobiol 44 49-4150

[23] Rubnitz JE(1995)A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia N Engl J Med 332 1678-932

[24] Kojima K(2016)Phase II results of Ara-C and idarubicin in combination with the selective inhibitor of nuclear export (SINE) compound selinexor (KPT-330) in patients with relapsed or refractory AML Blood 128 Abstract 341-505

[25] Kornblau SM(2016)First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors J Clin Oncol 34 4142-8

[26] Ruvolo V(2014)The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed /refractory non Hodgkin’s lymphoma (NHL) Blood 124 396-undefined

[27] Parikh K(2010)Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials BMC Cancer 10 337-undefined

[28] Cang S(1987)Cerebellar toxicity with high-dose cytosine arabinoside J Clin Oncol 5 927-undefined

[29] Sekhri A(1992)Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine J Natl Cancer Inst 84 500-undefined

[30] Liu D(2016)KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells Leukemia 31 1-undefined

[21] Ribeiro RC(2015)Combinatorial targeting of XPO1 and FLT3-ITD exerts synergistic anti-tumor effects in FLT3-mutated acute myeloid leukemias Blood 126 Abstract 1266-1683

[22] Pui CH(2006)Prognostic significance of Ki67-negative blast cell clone in the high risk group of children treated for acute myeloid leukaemia Folia Histochem Cytobiol 44 49-4150

[23] Rubnitz JE(1995)A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia N Engl J Med 332 1678-932

[24] Kojima K(2016)Phase II results of Ara-C and idarubicin in combination with the selective inhibitor of nuclear export (SINE) compound selinexor (KPT-330) in patients with relapsed or refractory AML Blood 128 Abstract 341-505

[25] Kornblau SM(2016)First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors J Clin Oncol 34 4142-8

[26] Ruvolo V(2014)The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed /refractory non Hodgkin’s lymphoma (NHL) Blood 124 396-undefined

[27] Parikh K(2010)Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials BMC Cancer 10 337-undefined

[28] Cang S(1987)Cerebellar toxicity with high-dose cytosine arabinoside J Clin Oncol 5 927-undefined

[29] Sekhri A(1992)Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine J Natl Cancer Inst 84 500-undefined

[30] Liu D(2016)KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells Leukemia 31 1-undefined